SynthesisThe oncologist2025
Prognostic value of miR-21 in colorectal cancer, pancreatic ductal adenocarcinoma, and esophageal squamous cell carcinoma: updated systematic review and meta-analysis.
Synthesis in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to conduct a systematic review of the prognostic value of miR-21 expression levels in patients with colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and esophageal squamous cell carcinoma (ESCC). METHODS AND
resultsWe searched the PubMed, Embase, and CENTRAL databases for relevant studies published up to August 25, 2023. Sixteen studies, totaling 3096 patients, were included. High miR-21 expression was associated with higher hazard ratio (HR) values and decreased overall survival (OS) in CRC and PDAC, but this effect was not statistically significant in ESCC. The pooled HRs for CRC, PDAC, and ESCC were 1.54 (95% confidence interval [CI]: 1.14-2.07; P = 0.004; I2 = 71%), 2.11 (95% CI: 1.81-2.46; P < 0.001; I2 = 0%), and 1.79 (95% CI: 0.82-3.92; P = 0.15; I2 = 75%), respectively. Patients with high miR-21 expression had higher HR values and decreased disease-free survival (DFS) compared to those with low miR-21 expression in all three cancer types. The pooled HRs for CRC, PDAC, and ESCC were 1.88 (95% CI: 1.36-2.60; P < 0.001; I2 = 59%), 2.04 (95% CI: 1.34-3.11; P < 0.001; I2 = 17%), and 1.77 (95% CI: 1.04-3.03; P = 0.04; I2 = 36%), respectively.
conclusionElevated miR-21 expression levels are associated with poorer OS and DFS in patients with CRC, pancreatic cancer, and esophageal cancer. However, due to heterogeneity in the results, further large-sample, high-quality studies are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.